FINWIRES · TerminalLIVE
FINWIRES

中国中信金融任命首席合规官

By

-- 据中信金融资产管理有限公司(HKG:2799)当日在香港交易所发布的公告显示,该公司任命刘泽云为首席合规官,该任命自周三生效。 周四下午交易中,该公司股价上涨超过1%。 刘泽云自2025年11月起担任该公司首席风险官,并自2025年12月起担任副总裁。

Related Articles

Research

Research Alert: Xpo Q1 Earnings Beat As Margins Expand And Tonnage Turns Positive

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:XPO reported Q1 EPS of $1.01 vs. $0.73 a year ago, beating consensus by $0.13, while revenue of $2.1B grew 7% and beat estimates by $60M. Adjusted EBITDA surged 15% to $319M, demonstrating accelerating momentum across the business. We believe the combination of margin expansion, positive volume inflection, and strong cash generation supports XPO's trajectory toward accelerating free cash flow generation. North American LTL performance was solid, with adjusted operating ratio improving 200 bps to 83.9% and 20% growth in adjusted operating income. Critically, tonnage per day turned positive at +0.1% vs. Q4 2025's -4.5% decline, marking an inflection point and suggesting early demand stabilization signs. Yield growth excluding fuel remained robust at 4.0%, supported by service improvements and AI-driven network optimization, while cash from operations grew 29% to $183M. In our view, XPO's insourcing strategy and operational leverage position the company well for continued margin expansion and cash flow growth.

$XPO
Research

Research Alert: Cigna: Mcr Improvement Supports Q1 Eps Beat, Guidance Raise

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CI reported Q1 2026 adjusted EPS of $7.79 (+16% Y/Y), beating the $7.61 consensus and prompting a $0.10 raise to annual EPS guidance. Total revenues rose 5% Y/Y to $68.5B, due to Evernorth Health Services' growth of 9% Y/Y to $58.4B, while Cigna Healthcare's revenues fell 21% Y/Y reflecting the Medicare business divestiture. The strong Evernorth performance, including 11% Y/Y growth in Pharmacy Benefit Services due to favorable drug mix and 6% Y/Y growth in Specialty and Care Services, supports the company's strategic pivot toward higher-margin services. Management maintained Medical Care Ratio guidance at 83.7%-84.7% for 2026, demonstrating continued cost discipline amid operational improvements. Operational efficiency improved with its SG&A expense ratio declining 100bps to 5.4%, while Cigna Healthcare pre-tax margins expanded 430bps to 13.2% and the Medical Care Ratio improved to 79.8% from 82.2%, primarily benefiting from the Medicare divestiture.

$CI
Research

JPMorgan Downgrades Kaiser Aluminum to Underweight From Neutral, Adjusts Price Target to $142 From $124

$KALU